FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079701876> ?p ?o ?g. }

• W2079701876 endingPage "39278" @default.
• W2079701876 startingPage "39272" @default.
• W2079701876 abstract "P-glycoprotein (P-gp) can transport a wide variety of cytotoxic compounds that have diverse structures. Therefore, the drug-binding domain of the human multidrug resistance P-gp likely consists of residues from multiple transmembrane (TM) segments. In this study, we completed cysteine-scanning mutagenesis of all the predicted TM segments of P-gp (TMs 1–5 and 7–10) and tested for inhibition by a thiol-reactive substrate (dibromobimane) to identify residues within the drug-binding domain. The activities of 189 mutants were analyzed. Verapamil-stimulated ATPase activities of seven mutants (Y118C and V125C (TM2), S222C (TM4), I306C (TM5), S766C (TM9), and I868C and G872C (TM10)) were inhibited by more than 50% by dibromobimane. The activities of mutants S222C (TM4), I306C (TM5), I868C (TM10), and G872C (TM10), but not that of mutants Y118C (TM2), V125C (TM2), and S776C (TM9), were protected from inhibition by dibromobimane by pretreatment with verapamil, vinblastine, or colchicine. These results and those from previous studies (Loo, T. W. and Clarke, D. M. (1997)J. Biol. Chem. 272, 31945–31948; Loo, T. W. and Clarke, D. M. (1999) J. Biol. Chem. 274, 35388–35392) indicate that the drug-binding domain of P-gp consists of residues in TMs 4, 5, 6, 10, 11, and 12. P-glycoprotein (P-gp) can transport a wide variety of cytotoxic compounds that have diverse structures. Therefore, the drug-binding domain of the human multidrug resistance P-gp likely consists of residues from multiple transmembrane (TM) segments. In this study, we completed cysteine-scanning mutagenesis of all the predicted TM segments of P-gp (TMs 1–5 and 7–10) and tested for inhibition by a thiol-reactive substrate (dibromobimane) to identify residues within the drug-binding domain. The activities of 189 mutants were analyzed. Verapamil-stimulated ATPase activities of seven mutants (Y118C and V125C (TM2), S222C (TM4), I306C (TM5), S766C (TM9), and I868C and G872C (TM10)) were inhibited by more than 50% by dibromobimane. The activities of mutants S222C (TM4), I306C (TM5), I868C (TM10), and G872C (TM10), but not that of mutants Y118C (TM2), V125C (TM2), and S776C (TM9), were protected from inhibition by dibromobimane by pretreatment with verapamil, vinblastine, or colchicine. These results and those from previous studies (Loo, T. W. and Clarke, D. M. (1997)J. Biol. Chem. 272, 31945–31948; Loo, T. W. and Clarke, D. M. (1999) J. Biol. Chem. 274, 35388–35392) indicate that the drug-binding domain of P-gp consists of residues in TMs 4, 5, 6, 10, 11, and 12. dibromobimane P-glycoprotein transmembrane The human multidrug resistance P-glycoprotein (P-gp)1 is located in the plasma membrane and uses ATP to pump a wide variety of structurally diverse cytotoxic compounds out of the cell (1Sharom F.J. J. Membr. Biol. 1997; 160: 161-175Crossref PubMed Scopus (417) Google Scholar, 2Ambudkar S.V. Dey S. Hrycyna C.A. Ramachandra M. Pastan I. Gottesman M.M. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 361-398Crossref PubMed Scopus (1929) Google Scholar). Expression of P-gp is relatively high in the epithelial cells of the gastrointestinal tract, renal proximal tubules, biliary tract, and capillaries of the brain and testes (3Thiebaut F. Tsuruo T. Hamada H. Gottesman M.M. Pastan I. Willingham M.C. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 7735-7738Crossref PubMed Scopus (2577) Google Scholar, 4Cordon-Cardo C. O'Brien J.P. Casals D. Rittman-Grauer L. Biedler J.L. Melamed M.R. Bertino J.R. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 695-698Crossref PubMed Scopus (1598) Google Scholar). The pattern of P-gp expression in tissues and studies on P-gp knockout mice indicate that the main physiological role of P-gp is to protect the organism from toxic xenobiotics (5Schinkel A.H. Smit J.J. van Tellingen O. Beijnen J.H. Wagenaar E. van Deemter L. Mol C.A. van der Valk M.A. Robanus-Maandag E.C. te Riele H.P. Berns A.J.M. Borst P. Cell. 1994; 77: 491-502Abstract Full Text PDF PubMed Scopus (2089) Google Scholar, 6Schinkel A.H. Semin. Cancer Biol. 1997; 8: 161-170Crossref PubMed Scopus (443) Google Scholar). The protective role of P-gp contributes to the phenomenon of multidrug resistance during cancer and AIDS chemotherapy because many of the therapeutic compounds are also substrates of P-gp (7Kim R.B. Fromm M.F. Wandel C. Leake B. Wood A.J. Roden D.M. Wilkinson G.R. J. Clin. Invest. 1998; 101: 289-294Crossref PubMed Scopus (1040) Google Scholar, 8Lee C.G. Gottesman M.M. Cardarelli C.O. Ramachandra M. Jeang K.T. Ambudkar S.V. Pastan I. Dey S. Biochemistry. 1998; 37: 3594-3601Crossref PubMed Scopus (460) Google Scholar, 9Robert J. Eur. J. Clin. Invest. 1999; 29: 536-545Crossref PubMed Scopus (71) Google Scholar). P-gp is a member of the ATP-binding cassette family of transporters (10Higgins C.F. Annu. Rev. Cell Biol. 1992; 8: 67-113Crossref PubMed Scopus (3386) Google Scholar, 11Holland I.B. Blight M.A. J. Mol. Biol. 1999; 293: 381-399Crossref PubMed Scopus (489) Google Scholar), and its 1280 amino acids are organized as two repeating units joined by a linker region of about 60 amino acids (12Chen C.J. Chin J.E. Ueda K. Clark D.P. Pastan I. Gottesman M.M. Roninson I.B. Cell. 1986; 47: 381-389Abstract Full Text PDF PubMed Scopus (1721) Google Scholar). Each repeat consists of an NH2-terminal hydrophobic domain containing six transmembrane (TM) segments followed by a hydrophilic domain containing an ATP-binding site (13Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 843-848Abstract Full Text Full Text PDF PubMed Scopus (262) Google Scholar, 14Kast C. Canfield V. Levenson R. Gros P. J. Biol. Chem. 1996; 271: 9240-9248Abstract Full Text Full Text PDF PubMed Scopus (129) Google Scholar). The exact mechanism of how P-gp functions is unknown. It is known, however, that both halves of the molecule are essential for activity (15Loo T.W. Clarke D.M. J. Biol. Chem. 1994; 269: 7750-7755Abstract Full Text PDF PubMed Google Scholar) and that both nucleotide-binding domains can bind and hydrolyze ATP and are essential for function (15Loo T.W. Clarke D.M. J. Biol. Chem. 1994; 269: 7750-7755Abstract Full Text PDF PubMed Google Scholar, 16Azzaria M. Schurr E. Gros P. Mol. Cell. Biol. 1989; 9: 5289-5297Crossref PubMed Scopus (270) Google Scholar, 17Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 22957-22961Abstract Full Text Full Text PDF PubMed Scopus (174) Google Scholar, 18Urbatsch I.L. Sankaran B. Bhagat S. Senior A.E. J. Biol. Chem. 1995; 270: 26956-26961Abstract Full Text Full Text PDF PubMed Scopus (231) Google Scholar, 19Hrycyna C.A. Ramachandra M. Ambudkar S.V. Ko Y.H. Pedersen P.L. Pastan I. Gottesman M.M. J. Biol. Chem. 1998; 273: 16631-16634Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar). The drug-binding domain is located in the TM domains of P-gp because drug substrates will bind to a deletion mutant lacking both nucleotide-binding domains (20Loo T.W. Clarke D.M. J. Biol. Chem. 1999; 274: 24759-24765Abstract Full Text Full Text PDF PubMed Scopus (134) Google Scholar). An important step in understanding the mechanism of P-gp is to determine the residues in the drug-binding domain. A common method for identifying residues in a membrane transporter that are critical for substrate binding and/or transport is to use alanine-scanning mutagenesis. This has been used successfully for transporters such as bacteriorhodopsin (21Subramaniam S. Curr. Opin. Struct. Biol. 1999; 9: 462-468Crossref PubMed Scopus (43) Google Scholar) and the SERCA1 calcium pump (22Clarke D.M. Loo T.W. Inesi G. MacLennan D.H. Nature. 1989; 339: 476-478Crossref PubMed Scopus (471) Google Scholar). Recent crystal structures of these two transporters showed that the amino acids involved in ligand binding are in agreement with those identified through mutational analyses (23Luecke H. Schobert B. Richter H.T. Cartailler J.P. Lanyi J.K. J. Mol. Biol. 1999; 291: 899-911Crossref PubMed Scopus (1310) Google Scholar, 24Toyoshima C. Nakasako M. Nomura H. Ogawa H. Nature. 2000; 405: 647-655Crossref PubMed Scopus (1619) Google Scholar). The residues in P-gp that are involved in drug binding, however, have been difficult to characterize because a large number of mutations throughout the molecule can alter the substrate specificity (25Loo T.W. Clarke D.M. J. Biol. Chem. 1993; 268: 3143-3149Abstract Full Text PDF PubMed Google Scholar, 26Loo T.W. Clarke D.M. J. Biol. Chem. 1993; 268: 19965-19972Abstract Full Text PDF PubMed Google Scholar, 27Loo T.W. Clarke D.M. J. Biol. Chem. 1994; 269: 7243-7248Abstract Full Text PDF PubMed Google Scholar, 28Taguchi Y. Morishima M. Komano T. Ueda K. FEBS Lett. 1997; 413: 142-146Crossref PubMed Scopus (25) Google Scholar, 29Beaudet L. Gros P. J. Biol. Chem. 1995; 270: 17159-17170Abstract Full Text Full Text PDF PubMed Scopus (74) Google Scholar, 30Hanna M. Brault M. Kwan T. Kast C. Gros P. Biochemistry. 1996; 35: 3625-3635Crossref PubMed Scopus (55) Google Scholar, 31Kwan T. Gros P. Biochemistry. 1998; 37: 3337-3350Crossref PubMed Scopus (42) Google Scholar). It has been difficult to determine whether mutations that affected activity were actually close to the drug-binding site or whether they affected the global structure of the protein (32Ramachandra M. Ambudkar S.V. Gottesman M.M. Pastan I. Hrycyna C.A. Mol. Biol. Cell. 1996; 7: 1485-1498Crossref PubMed Scopus (68) Google Scholar). To avoid these difficulties, we used a direct assay involving cysteine-scanning mutagenesis and modification with a thiol-reactive substrate to identify residues in the TM segments that are critical for drug binding. The rationale is that the thiol-reactive substrate, dibromobimane (dBBn), will enter the drug-binding site of P-gp, covalently label any adjacent cysteine residue, and inhibit activity. Inhibition by dBBn should be preventable by pretreatment with other substrates such as verapamil, colchicine, and vinblastine if the reactive residue is in the drug-binding domain. We have used this method and identified the residues important for drug binding in TMs 6, 11, and 12 (33, 34). In this study, we identify important residues in the remaining TM segments (TMs 1–5 and 7–10) that are important for activity. Wild-type P-gp has cysteine residues at positions 137, 431, 717, 956, 1074, 1125, and 1227. None of these cysteines are important for activity because mutation of all cysteines to alanine (Cys-less P-gp) resulted in an active molecule (13Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 843-848Abstract Full Text Full Text PDF PubMed Scopus (262) Google Scholar). The Cys-less P-gp cDNA was modified to code for 10 histidine residues at the COOH end of the molecule (Cys-less P-gp(His)10). This facilitated purification of the Cys-less P-gp by nickel-chelate chromatography (35Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 21449-21452Abstract Full Text Full Text PDF PubMed Scopus (191) Google Scholar). Cysteine residues were then introduced into the Cys-less P-gp(His)10 as described previously (36Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 20986-20989Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar). The integrity of the mutated cDNA was confirmed by sequencing the entire cDNA (37Sanger F. Nicklen S. Coulson A.R. Proc. Natl. Acad. Sci. U. S. A. 1977; 74: 5463-5467Crossref PubMed Scopus (52769) Google Scholar). Expression and purification of histidine-tagged P-gp mutants were done as described previously (35Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 21449-21452Abstract Full Text Full Text PDF PubMed Scopus (191) Google Scholar). Briefly, fifty 10-cm-diameter culture plates of HEK 293 cells were transfected with the mutant cDNA. After 24 h, the medium was replaced with fresh medium containing 10 μm cyclosporin A. P-gp was expressed in the presence of cyclosporin A because it is a drug substrate that promotes maturation of the protein (38Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 709-712Abstract Full Text Full Text PDF PubMed Scopus (220) Google Scholar). The transfected cells were harvested 24 h later and solubilized with 1% (w/v)n-dodecyl-β-d-maltoside, and the mutant P-gp was isolated by nickel-chelate chromatography (Ni-NTA columns; Qiagen, Inc., Mississauga, Canada). The P-gp(His)10 mutants were eluted from the nickel columns with buffer containing 10 mm Tris-HCl, pH 7.5, 500 mm NaCl, 300 mm imidazole (pH 7.0), 0.1% (w/v)n-dodecyl-β-d-maltoside, and 10% (v/v) glycerol and mixed with an equal volume of 10 mg/ml sheep brain phosphatidylethanolamine (Type II-S; Sigma-Aldrich) that was washed and suspended in 10 mm Tris-HCl, pH 7.5, and 150 mmNaCl. The P-gp:lipid mixture was then sonicated for 45 s at 4 °C (bath-type probe; maximum setting, Branson Sonifier 450; Branson Ultrasonic, Danbury, CT). An aliquot of the sonicated P-gp:lipid mixture was assayed for drug-stimulated ATPase activity by addition of an equal volume of buffer containing 100 mmTris-HCl, pH 7.5, 100 mm NaCl, 20 mmMgCl2, 10 mm ATP, and the desired drug substrates (2 mm verapamil, 0.2 mm vinblastine, or 10 mm colchicine). The samples were incubated for 30 min at 37 °C, and the amount of inorganic phosphate liberated was determined by the method of Chifflet et al. (39Chifflet S. Torriglia A. Chiesa R. Tolosa S. Anal. Biochem. 1988; 168: 1-4Crossref PubMed Scopus (418) Google Scholar). For inhibition with dBBn, the P-gp:lipid mixture was preincubated with 2 mm dBBn (Molecular Probes, Inc.) for 5 min at 37 °C. The reaction was stopped by the addition of cysteine, pH 7.5, to a final concentration of 40 mm. Drug-stimulated ATPase activity was then determined as described above. In the protection experiments, the P-gp:lipid samples were treated with 2 mmverapamil, 0.2 mm vinblastine, or 10 mmcolchicine for 15 min at 4 °C before the addition of dBBn (the final concentration of dBBn was 0.2 mm or 2 mm). These were saturating substrate concentrations for stimulation of ATPase activity, whereas 0.2 mm is theKm for stimulation by dBBn (33Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 31945-31948Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar, 34Loo T.W. Clarke D.M. J. Biol. Chem. 1999; 274: 35388-35392Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). The samples were then incubated with 0.2 or 2 mm dBBn for 5 min at 37 °C, and the reaction was stopped by the addition of cysteine, pH 7.5 (final concentration, 40 mm). Drug-stimulated ATPase activity was then determined with the same drug used for protection (final concentrations were 1 mm verapamil, 0.1 mm vinblastine, or 5 mm colchicine). The purified histidine-tagged P-gp was subjected to SDS-polyacrylamide gel electrophoresis, transferred onto a sheet of nitrocellulose, and probed with a rabbit polyclonal antibody against P-gp, followed by enhanced chemiluminescence (36Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 20986-20989Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar). There is increasing evidence that the drug-binding site is likely to be within the TM segments (20Loo T.W. Clarke D.M. J. Biol. Chem. 1999; 274: 24759-24765Abstract Full Text Full Text PDF PubMed Scopus (134) Google Scholar, 40Raviv Y. Pollard H.B. Bruggemann E.P. Pastan I. Gottesman M.M. J. Biol. Chem. 1990; 265: 3975-3980Abstract Full Text PDF PubMed Google Scholar, 41Homolya L. Hollo Z. Germann U.A. Pastan I. Gottesman M.M. Sarkadi B. J. Biol. Chem. 1993; 268: 21493-21496Abstract Full Text PDF PubMed Google Scholar, 42Greenberger L.M. J. Biol. Chem. 1993; 268: 11417-11425Abstract Full Text PDF PubMed Google Scholar, 43Demmer A. Thole H. Kubesch P. Brandt T. Raida M. Fislage R. Tummler B. J. Biol. Chem. 1997; 272: 20913-20919Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar, 44Chen G. Duran G.E. Steger K.A. Lacayo N.J. Jaffrezou J.P. Dumontet C. Sikic B.I. J. Biol. Chem. 1997; 272: 5974-5982Abstract Full Text Full Text PDF PubMed Scopus (83) Google Scholar). The amino acids predicted to be in TM segments are shown in Fig. 1. We had reported that residues within TMs 6, 11, and 12 were important for drug binding (33Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 31945-31948Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar, 34Loo T.W. Clarke D.M. J. Biol. Chem. 1999; 274: 35388-35392Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). In this study, we used cysteine-scanning mutagenesis of the remaining TM segments and inhibition by dBBn to identify residues that contribute to the drug-binding domain. Accordingly, each residue in TMs 1, 2, 3, 4, 5, 7, 8, 9, and 10 was changed to cysteine, and then we determined whether the mutant protein was active. The mutant P-gps were expressed in HEK 293 cells, purified by nickel-chelate chromatography, and assayed for verapamil-stimulated ATPase activity. We chose verapamil as the substrate because it had the highest stimulation of the ATPase activity of Cys-less P-gp (about 13-fold; Ref. 33Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 31945-31948Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar). Substrate-stimulated ATPase activity has been shown to correlate well with transport because the turnover numbers are similar (45Ambudkar S.V. Cardarelli C.O. Pashinsky I. Stein W.D. J. Biol. Chem. 1997; 272: 21160-21166Abstract Full Text Full Text PDF PubMed Scopus (173) Google Scholar). Fig. 2 shows the verapamil-stimulated ATPase activity of each Cys mutant after treatment with dibromobimane. A total of 189 Cys mutants were analyzed. Six mutants, V52C (TM1), G54C (TM1), G62C (TM1), G122C (TM2), G763C (TM8), and P866C (TM10), were not analyzed because of low expression or very low activity. The mutants V52C, G54C, and G62C appeared to be defective in processing and were not efficiently expressed compared with Cys-less P-gp(His)10. Blots of whole cell extracts of HEK 293 cells expressing these mutants showed very low amounts of the immature (150-kDa) form of P-gp (data not shown). Expression of these TM1 mutants in the presence of cyclosporin A induced maturation of the 150-kDa protein to the mature 170-kDa P-gp, but the yields were too low to allow accurate measurement of drug-stimulated ATPase activity. The remaining 186 P-gp mutants were expressed as well as Cys-less P-gp(His)10. Three of these mutants (G122C, G763C, and P866C) exhibited less than 20% of the verapamil-stimulated ATPase activity of Cys-less P-gp(His)10. Mutants G122C (TM2), G763C (TM8), and P866C (TM10) had 9%, 11%, and 6%, respectively, of the verapamil-stimulated ATPase activity of Cys-less P-gp(His)10. It is interesting that mutants G122C (TM2) and G763C (TM8) occupy equivalent positions in each half of P-gp. We reported previously that mutation of P866A caused drastic alteration in the substrate specificity of P-gp (25Loo T.W. Clarke D.M. J. Biol. Chem. 1993; 268: 3143-3149Abstract Full Text PDF PubMed Google Scholar).Figure 2Inhibition of verapamil-stimulated ATPase activity by dBBn. Histidine-tagged mutants were purified by nickel-chelate chromatography, mixed with lipid, sonicated, and then incubated for 5 min at 37 °C with or without 2 mm dBBn. The reaction was quenched by the addition of cysteine, and then the verapamil-stimulated ATPase activity was determined. The results (percentage of untreated) are expressed relative to that of a mock-treated sample. The verapamil-stimulated activity (with no dBBn) of each mutant relative to Cys-less P-gp(His)10 is shown in the lower box. Each value is the average of two different purifications. The deviation from the mean is shown. A–Ishow the activities of mutants in TMs 1, 2, 3, 4, 5, 7, 8, 9, and 10, respectively. ND, not done because of very low activity.View Large Image Figure ViewerDownload Hi-res image Download (PPT) The 183 mutants that had expression levels similar to that of Cys-less P-gp(His)10and had greater than 20% of the verapamil-stimulated ATPase activity of Cys-less P-gp(His)10 were tested for inhibition by dBBn. Dibromobimane is a substrate of P-gp, and its reaction with a cysteine within the drug-binding site would be expected to result in the inhibition of verapamil-stimulated ATPase activity. The mutant P-gps were isolated by nickel-chelate chromatography, mixed with lipid, sonicated, and incubated for 5 min at 37 °C with dBBn. The reaction was stopped by the addition of cysteine to quench the reactivity of dBBn and convert it to a compound that was no longer a substrate of P-gp (33Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 31945-31948Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar). The verapamil-stimulated ATPase activities of the dBBn-treated samples were assayed and compared with that of mock-treated samples. The results for each TM segment are shown in Fig. 2, A–I. In TM1 (Fig. 2 A), the active mutants retained more than 80% of their ATPase activity after treatment with dBBn. Two mutants in TM2 (Fig. 2 B) were substantially inhibited by dBBn. Mutants Y118C and V125C were inhibited 84% and 67%, respectively, by dBBn. The results for TM3 (Fig. 2 C) were similar to those in TM1 in that all of the mutants retained more than 80% of their activity after treatment with dBBn. In TM4 (Fig. 2 D), the activity of one mutant, S222C, was inhibited by 75% after exposure to dBBn. In TM5 (Fig. 2 E), there were modest decreases in activity (about 25–30%) for mutants A295C and S298C, whereas the remaining mutants retained more than 80% of their activity after treatment with dBBn. Although mutant I306C (TM5) had only 26% of the verapamil-stimulated ATPase activity of Cys-less P-gp(His)10, its basal ATPase activity was increased (about 2-fold) upon treatment with dBBn (data not shown). Its verapamil-stimulated ATPase activity also increased to 130% after treatment with dBBn. TM7 (Fig. 2 F), the first TM in the COOH half of P-gp, showed results similar to those for TM1 in that all the mutants were quite resistant to inhibition by dBBn (all retained greater than 80% of their activity). Similarly, the pattern of inhibition in TM8 mutants (Fig. 2 G) was very similar to that seen with TM2 mutants (Fig. 2 B). Mutating the residues at the fifth position, G122C (TM2) and G736C (TM8), resulted in significant reductions in the verapamil-stimulated ATPase activities (9% and 11%, respectively), whereas mutating the residues at the eighth position, V125C (TM2) and S766C (TM8), resulted in mutants that were sensitive to inhibition by dBBn (67% and 81% inhibition, respectively). The Cys mutants in TM9 (Fig. 2 H) were relatively resistant to inhibition by dBBn, with the most sensitive mutants, A834C and V835C, showing about 25% inhibition. Two mutants, I868C and G872C in TM10 (Fig. 2 I), were very sensitive to inhibition by dBBn. Their activities were inhibited by 80% and 75%, respectively. The concentrations of dBBn required to give 50% inhibition of verapamil-stimulated ATPase activity for mutants Y118C (TM2), V125C (TM2), S222C (TM4), S766C (TM8), I868C (TM10), and G872C (TM10) were 740, 870, 340, 92, 80 and 62 μm, respectively. Immunoblot analysis of cells expressing these mutants P-gps showed that the expression was similar to that of Cys-less P-gp (Fig. 3). In all cases, the major product was the mature 170-kDa protein. Although the initial results identified residues within the predicted TM segments that were sensitive to inhibition by dBBn, it was possible that these cysteines were very accessible to dBBn and may not be close to the drug-binding site. To ensure that inhibition was indeed due to inhibition of a residue in the drug-binding site, it was important to show that the presence of a substrate would protect the mutant P-gp from inhibition by dBBn. Accordingly, three substrates, verapamil, vinblastine, and colchicine, were selected for the protection experiments. Verapamil was selected because it was used in the inhibition assays and showed the highest stimulation of activity. Vinblastine and colchicine were also included because they are structurally different from verapamil and have traditionally been used to study mutants of P-gp (25Loo T.W. Clarke D.M. J. Biol. Chem. 1993; 268: 3143-3149Abstract Full Text PDF PubMed Google Scholar, 26Loo T.W. Clarke D.M. J. Biol. Chem. 1993; 268: 19965-19972Abstract Full Text PDF PubMed Google Scholar, 27Loo T.W. Clarke D.M. J. Biol. Chem. 1994; 269: 7243-7248Abstract Full Text PDF PubMed Google Scholar, 46Loo T.W. Clarke D.M. Biochemistry. 1994; 33: 14049-14057Crossref PubMed Scopus (127) Google Scholar). We have used colchicine and vinblastine to characterize the residues in TMs 6, 11, and 12 that were sensitive to inhibition by dBBn (33Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 31945-31948Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar, 34Loo T.W. Clarke D.M. J. Biol. Chem. 1999; 274: 35388-35392Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). Six mutants that were inhibited by dBBn, Y118C (TM2), V125C (TM2), S222 (TM4), S766C (TM8), I868C (TM10), and G872C (TM10), were tested for their ability to be protected from inhibition by dBBn in the presence of substrate. Mutant I306C (TM5) was also chosen because its basal ATPase activity was increased after treatment with dBBn (data not shown). Fig. 4 A shows that dBBn treatment also inhibited the vinblastine- and colchicine-stimulated ATPase activities of the mutants, with the exception of mutant I306C. Dibromobimane inhibited the vinblastine-stimulated ATPase activity of I306C, whereas the verapamil- and colchicine-stimulated activities were increased (130% and 125%, respectively). To test for protection by drug substrates, the mutants were preincubated with verapamil (2 mm), vinblastine (0.2 mm), or colchicine (10 mm) and then treated with dBBn for 5 min at 37 °C, and the reaction was quenched with cysteine. The mutants (S766C, I868C, and G872C) that were more sensitive to low concentrations of dBBn were treated with 0.2 mm dBBn, whereas the others (Y118C, V125C, S222C, and I306C) were treated with 2 mm dBBn. Drug-stimulated ATPase activity was then determined with the same drug used for protection. The results are shown in Fig. 4 B. Most protection by substrate was observed for mutant S222C (TM4). The mutant was almost completely protected from inactivation by dBBn in the presence of vinblastine. Similarly, vinblastine protected mutant G872C (TM10) from inactivation by dBBn because more than 80% of the activity remained. G872C (TM10) was modestly protected by verapamil, whereas colchicine offered little protection. All three substrates also showed modest protection of mutant I868C (TM10). Some protection from dBBn inhibition by vinblastine was observed for mutant I306C. There was little or no protection by any of the drug substrates for mutants Y118C (TM2), V125C (TM2), and S766C (TM8). We were not able to accurately determine whether the basal ATPase activity of mutants Y118C, V125C, or S766C was inhibited dBBn because the basal ATPase activities were too low. To test whether differences in membrane fluidity affected the drug protection characteristics of the mutants, the assays were repeated at room temperature. The samples were preincubated with verapamil, vinblastine, or colchicine for 15 min at room temperature and treated with dBBn for 15 min at room temperature, and then the ATPase activity was measured at 37 °C. The results were similar to those shown in Fig. 4 (data not shown). We studied drug-binding by measuring inhibition of ATPase activity of P-gp mutants containing a single cysteine. Cys-less P-gp is a good model system because the mutant could still confer resistance to a wide variety of cytotoxic substrates (13Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 843-848Abstract Full Text Full Text PDF PubMed Scopus (262) Google Scholar), and it retains about 80% of the drug-stimulated ATPase activity of wild-type enzyme (35Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 21449-21452Abstract Full Text Full Text PDF PubMed Scopus (191) Google Scholar). A potential drawback of this approach is that the assay measures only inhibition of ATPase activity and may not reflect drug transport activity. However, drug-stimulated ATPase activity appears to reflect transport activity because the turnover number for vinblastine-stimulated ATPase activity correlates with vinblastine transport out of the cell (45Ambudkar S.V. Cardarelli C.O. Pashinsky I. Stein W.D. J. Biol. Chem. 1997; 272: 21160-21166Abstract Full Text Full Text PDF PubMed Scopus (173) Google Scholar). This study shows that residues S222C (TM4), I306C (TM5), I868C (TM10), and G872C (TM10) may be important for drug binding. We have reported that residues L339C and A342C in TM6, F942C and T945C in TM11, and L975C, V982C, and A985C in TM12 are important for drug binding (33Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 31945-31948Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar, 34Loo T.W. Clarke D.M. J. Biol. Chem. 1999; 274: 35388-35392Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). In trying to understand how residues that are quite distant from each other could form the drug-binding site, we have aligned the residues in each TM segment as α-helical wheels. In Fig. 5, we have aligned the residues that are sensitive to inhibition by dBBn such that they face toward the center of the molecule. It is interesting to note that the dBBn-sensitive residues also lie on one face of the helix. Fig. 5 also takes into consideration the results from disulfide cross-linking studies that show that TMs 4–6 and 10–12 are close to one another (47Loo T.W. Clarke D.M. J. Biol. Chem. 2000; 275: 5253-5256Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar). Residues S222 (TM4) and I868 (TM10) were protected from inhibition by dBBn by verapamil, vinblastine, and colchicine. This indicates that S222 and I868 may be common to the binding of all three substrates. In contrast, residue G872 (TM10), which lies on the same helical face as I868 (TM10), was protected by verapamil and vinblastine but not by colchicine and may be involved in the binding of verapamil and vinblastine. Residue I306 may be important for drug binding because of the effect of dBBn on the vinblastine-stimulated ATPase activity of mutant I306C. Dibromobimane inhibited the vinblastine-stimulated activity of this mutant, but not its verapamil- or colchicine-stimulated activity. Vinblastine also protected the mutant from inactivation by dBBn. Disulfide cross-linking data support TM5 being part of the drug-binding domain. Increases in verapamil- and colchicine-stimulated activities after reaction of residues I306C with dBBn could also be an indication that I306 is close to or within the drug-binding site. It is also possible that modification of a residue within or close to the drug-binding domain could lead to inhibition or stimulation of ATPase activity. Residues Ala295 (TM5) and Ile299 (TM5) lie on either side of Ile306 in the helical wheel model (Fig. 5) and could be cross-linked to residues in TM12 (47Loo T.W. Clarke D.M. J. Biol. Chem. 2000; 275: 5253-5256Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar). Cross-linking of I299C (TM5) to residues in TM12 was inhibited by vinblastine and promoted by verapamil and colchicine. Assignment of TMs 4, 5, and 10 as part of the drug-binding domain of P-gp is consistent with the results obtained from mutation and labeling studies with radioactive analogs of photoactive substrates. Mutation of prolines at equivalent positions in TM4 (P223) and TM10 (P866) caused large alterations in the substrate specificity of the protein (25Loo T.W. Clarke D.M. J. Biol. Chem. 1993; 268: 3143-3149Abstract Full Text PDF PubMed Google Scholar). The mutants L210I, K209E, and I214T in TM4 of mouse mdr3 (31Kwan T. Gros P. Biochemistry. 1998; 37: 3337-3350Crossref PubMed Scopus (42) Google Scholar) and I299M (48Shoshani T. Zhang S. Dey S. Pastan I. Gottesman M.M. Mol. Pharmacol. 1998; 54: 623-630PubMed Google Scholar) and L305A, S, or T in TM5 of human P-gp also changed the substrate specificity of the transporter (49Loo T.W. Clarke D.M. Methods Enzymol. 1998; 292: 480-492Crossref PubMed Scopus (20) Google Scholar). The yeast homolog of human P-gp is Pdr5. It is also an ATP-binding cassette transporter, and many of the substrates of P-gp are also substrates of Pdr5 (50Balzi E. Wang M. Leterme S. Van Dyck L. Goffeau A. J. Biol. Chem. 1994; 269: 2206-2214Abstract Full Text PDF PubMed Google Scholar). Random mutagenesis studies on Pdr5 showed that residue 1360 in predicted TM10 was important for interaction with FK506 (51Egner R. Rosenthal F.E. Kralli A. Sanglard D. Kuchler K. Mol. Biol. Cell. 1998; 9: 523-543Crossref PubMed Scopus (134) Google Scholar). This residue aligns with residue Leu861 (TM10) of human P-gp and faces toward the drug-binding domain in Fig. 5. TMs 4 and 5 are also labeled by photoactive derivatives of iodomycin (43Demmer A. Thole H. Kubesch P. Brandt T. Raida M. Fislage R. Tummler B. J. Biol. Chem. 1997; 272: 20913-20919Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar) and forskolin (52Morris D.I. Greenberger L.M. Bruggemann E.P. Cardarelli C. Gottesman M.M. Pastan I. Seamon K.B. Mol. Pharmacol. 1994; 46: 329-337PubMed Google Scholar). DBBn also inhibited P-gp by reacting with cysteines in TM2 (Y118C and V125C) and TM8 (S766C). The drug substrates verapamil, vinblastine, and colchicine did not protect these mutants from inhibition by dBBn. It is possible that some of these residues do not lie within the drug-binding site for these compounds because relatively high concentrations of dBBn were needed to inhibit 50% of the activity of mutants Y118C (TM2) and V125C (TM2) (740 and 870 μm, respectively). Another possibility is that modification of mutant Y118C, V125C, or S766C blocks an essential conformational change during coupling of drug binding to ATPase activity. Residue Tyr118lies close to a conformationally sensitive residue, Arg113(53Loo T.W. Clarke D.M. J. Biol. Chem. 1998; 273: 32373-32376Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar). It is also possible that these residues lie within another drug-binding site or modulator site. The results from several studies suggest that P-gp may contain up to four different drug interaction sites (54Dey S. Ramachandra M. Pastan I. Gottesman M.M. Ambudkar S.V. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 10594-10599Crossref PubMed Scopus (359) Google Scholar, 55Pascaud C. Garrigos M. Orlowski S. Biochem. J. 1998; 333: 351-358Crossref PubMed Scopus (140) Google Scholar, 56Shapiro A.B. Fox K. Lam P. Ling V. Eur. J. Biochem. 1999; 259: 841-850Crossref PubMed Scopus (285) Google Scholar). In one model of transport, the substrates occupy two different drug-binding sites during transport (54Dey S. Ramachandra M. Pastan I. Gottesman M.M. Ambudkar S.V. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 10594-10599Crossref PubMed Scopus (359) Google Scholar). In other models, different substrates interact with separate binding sites (56Shapiro A.B. Fox K. Lam P. Ling V. Eur. J. Biochem. 1999; 259: 841-850Crossref PubMed Scopus (285) Google Scholar). In both models, ATP hydrolysis leads to drug efflux. It has been reported that two to three molecules of ATP are hydrolyzed for every molecule of vinblastine transported (45Ambudkar S.V. Cardarelli C.O. Pashinsky I. Stein W.D. J. Biol. Chem. 1997; 272: 21160-21166Abstract Full Text Full Text PDF PubMed Scopus (173) Google Scholar). Another way of explaining how P-gp can transport such a large variety of structurally different compounds is to assume that different residues in the TMs contribute to the binding of a particular substrate. This may be possible because of the flexibility of the TM segments. Studies have shown that the TMs are quite flexible at 37 °C because cross-linking results indicate that residues in TM6 can cross-link residues in TMs 10, 11, and 12, whereas residues in TM12 can cross-link residues in TMs, 4, 5, and 6 (36Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 20986-20989Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar, 47Loo T.W. Clarke D.M. J. Biol. Chem. 2000; 275: 5253-5256Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar). It is possible that binding of a particular compound causes an “induced-fit” binding site by reducing the flexibility of the TMs and thereby contributing different residues to the binding of a particular substrate. Such an induced-fit binding site model has also been proposed for the BmrR transcription factor that can bind a wide variety of compounds (57Zheleznova E.E. Markham P.N. Neyfakh A.A. Brennan R.G. Cell. 1999; 96: 353-362Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar). This model is also consistent with the observation that various structurally diverse drug substrates can induce correct folding of P-gp-processing mutants that have mutations in all parts of the molecule (38Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 709-712Abstract Full Text Full Text PDF PubMed Scopus (220) Google Scholar). The drug substrates can do this by inducing superfolding of the transmembrane domains (58Loo T.W. Clarke D.M. J. Biol. Chem. 1998; 273: 14671-14674Abstract Full Text Full Text PDF PubMed Scopus (96) Google Scholar). The ability to rescue P-gp-processing mutants with different substrates indicates that there is at least one site or overlapping site that can be occupied by most substrates. This is supported by the finding that several residues (this study and Refs. 33Loo T.W. Clarke D.M. J. Biol. Chem. 1997; 272: 31945-31948Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar and 34Loo T.W. Clarke D.M. J. Biol. Chem. 1999; 274: 35388-35392Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar) can be protected from inhibition by dBBn with verapamil, vinblastine, and colchicine. Further work with other substrates and compounds that are not transported by P-gp will be needed to clarify whether P-gp contains one drug-binding site with broad specificity or multiple sites with distinct specificities. We thank Dr. Randal Kaufman (Genetics Institute, Boston, MA) for pMT21. We thank Claire Bartlett for assistance with tissue culture." @default.
• W2079701876 created "2016-06-24" @default.
• W2079701876 creator A5042609718 @default.
• W2079701876 creator A5060459035 @default.
• W2079701876 date "2000-12-01" @default.
• W2079701876 modified "2023-10-01" @default.
• W2079701876 title "Identification of Residues within the Drug-binding Domain of the Human Multidrug Resistance P-glycoprotein by Cysteine-scanning Mutagenesis and Reaction with Dibromobimane" @default.
• W2079701876 cites W1494833279 @default.
• W2079701876 cites W1542671610 @default.
• W2079701876 cites W1561870857 @default.
• W2079701876 cites W1577612357 @default.
• W2079701876 cites W1591356314 @default.
• W2079701876 cites W1594196316 @default.
• W2079701876 cites W1598654033 @default.
• W2079701876 cites W1687425191 @default.
• W2079701876 cites W1964286235 @default.
• W2079701876 cites W1964470226 @default.
• W2079701876 cites W1971074779 @default.
• W2079701876 cites W1979565452 @default.
• W2079701876 cites W1981871034 @default.
• W2079701876 cites W1982857971 @default.
• W2079701876 cites W1983833280 @default.
• W2079701876 cites W1983956828 @default.
• W2079701876 cites W1985006115 @default.
• W2079701876 cites W1989023531 @default.
• W2079701876 cites W1992531404 @default.
• W2079701876 cites W1996803443 @default.
• W2079701876 cites W2002077468 @default.
• W2079701876 cites W2003623971 @default.
• W2079701876 cites W2018755505 @default.
• W2079701876 cites W2019113077 @default.
• W2079701876 cites W2020084384 @default.
• W2079701876 cites W2023703396 @default.
• W2079701876 cites W2024735070 @default.
• W2079701876 cites W2033526989 @default.
• W2079701876 cites W2036873028 @default.
• W2079701876 cites W2040809334 @default.
• W2079701876 cites W2045689507 @default.
• W2079701876 cites W2045831118 @default.
• W2079701876 cites W2047118695 @default.
• W2079701876 cites W2047734909 @default.
• W2079701876 cites W2055634974 @default.
• W2079701876 cites W2060914976 @default.
• W2079701876 cites W2062133534 @default.
• W2079701876 cites W2072412837 @default.
• W2079701876 cites W2078877172 @default.
• W2079701876 cites W2086602165 @default.
• W2079701876 cites W2090910729 @default.
• W2079701876 cites W2098142549 @default.
• W2079701876 cites W2112001901 @default.
• W2079701876 cites W2115357061 @default.
• W2079701876 cites W2124305630 @default.
• W2079701876 cites W2128528171 @default.
• W2079701876 cites W2131403498 @default.
• W2079701876 cites W2138270253 @default.
• W2079701876 cites W2153331570 @default.
• W2079701876 cites W2153712534 @default.
• W2079701876 cites W2162097287 @default.
• W2079701876 cites W2247265389 @default.
• W2079701876 cites W2512279504 @default.
• W2079701876 cites W4235162835 @default.
• W2079701876 cites W86821847 @default.
• W2079701876 doi "https://doi.org/10.1074/jbc.m007741200" @default.
• W2079701876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11013259" @default.
• W2079701876 hasPublicationYear "2000" @default.
• W2079701876 type Work @default.
• W2079701876 sameAs 2079701876 @default.
• W2079701876 citedByCount "123" @default.
• W2079701876 countsByYear W20797018762012 @default.
• W2079701876 countsByYear W20797018762013 @default.
• W2079701876 countsByYear W20797018762014 @default.
• W2079701876 countsByYear W20797018762015 @default.
• W2079701876 countsByYear W20797018762016 @default.
• W2079701876 countsByYear W20797018762017 @default.
• W2079701876 countsByYear W20797018762018 @default.
• W2079701876 countsByYear W20797018762019 @default.
• W2079701876 countsByYear W20797018762020 @default.
• W2079701876 countsByYear W20797018762021 @default.
• W2079701876 countsByYear W20797018762022 @default.
• W2079701876 countsByYear W20797018762023 @default.
• W2079701876 crossrefType "journal-article" @default.
• W2079701876 hasAuthorship W2079701876A5042609718 @default.
• W2079701876 hasAuthorship W2079701876A5060459035 @default.
• W2079701876 hasBestOaLocation W20797018761 @default.
• W2079701876 hasConcept C104317684 @default.
• W2079701876 hasConcept C108625454 @default.
• W2079701876 hasConcept C116834253 @default.
• W2079701876 hasConcept C133936738 @default.
• W2079701876 hasConcept C16318435 @default.
• W2079701876 hasConcept C181199279 @default.
• W2079701876 hasConcept C185592680 @default.
• W2079701876 hasConcept C2778707650 @default.
• W2079701876 hasConcept C2779201268 @default.
• W2079701876 hasConcept C2780227090 @default.
• W2079701876 hasConcept C501593827 @default.
• W2079701876 hasConcept C501734568 @default.
• W2079701876 hasConcept C55493867 @default.
• W2079701876 hasConcept C59822182 @default.

• next